Rotavirus P Genotypes Specific Neutra™ Antibody Products

Are you currently facing long drug development cycles, difficulty in characterizing viral entry, or challenges in broad-spectrum antibody development against diverse viral strains? Our Rotavirus P genotypes Specific Neutra™ Antibody Products help you accelerate vaccine research and develop highly specific therapeutics through advanced epitope mapping and high-throughput neutralization screening platforms.

Introduction of Rotavirus P Genotypes

Rotavirus (RV) remains a leading cause of severe acute gastroenteritis in infants and young children worldwide, responsible for a significant global health burden. The virus is a non-enveloped, double-stranded RNA (dsRNA) virus characterized by a triple-layered capsid. The outermost layer is composed of two primary structural proteins: VP7 (a glycoprotein defining G genotypes) and VP4 (a protease-sensitive protein defining P genotypes).

Structure and Function of VP4

VP4 is an 88 kDa spike protein that projects from the VP7 shell. It is the primary mediator of viral attachment and penetration. To become infectious, VP4 must be proteolytically cleaved by trypsin into two subunits: VP8* (the head subunit), which is responsible for initial host cell attachment by interacting with sialic acid or histo-blood group antigens (HBGAs), and VP5* (the body/foot subunit), which anchors the spike and facilitates membrane penetration through a dramatic conformational transition.

Fig.1 Rotavirus structure.¹

VP4 Signaling

Rotavirus VP4 is the spike protein responsible for cell attachment and penetration. Proteolytic cleavage of VP4 into VP5* and VP8* is essential for infectivity.

VP4 interacts with various receptors, including integrins and hsc70, triggering PI3K/Akt and MAPK/ERK signaling pathways. These signals facilitate viral internalization via endocytosis and regulate calcium homeostasis by mobilizing intracellular Ca²⁺ stores. This calcium signaling is crucial for disrupting the host cytoskeleton and activating NF-κ, which modulates the innate immune response and promotes efficient viral replication.

Genotypic Diversity and Clinical Impact

To date, dozens of P genotypes have been identified (P[1]–P[58]). In humans, P[8] is the most prevalent genotype globally, followed by P[4] and P[6]. The diversity of these genotypes significantly impacts vaccine efficacy; for instance, the emergence of G2P[4] or equine-like strains can challenge existing vaccination programs. Clinical manifestations range from mild diarrhea to severe dehydration and death, emphasizing the need for targeted neutralizing agents that can block the VP4-mediated entry pathway.

Applications of Anti-Rotavirus P Genotypes Neutralizing Antibodies

Neutralizing antibodies against VP4 are indispensable tools in both therapeutic development and virological research. Their applications include:

• Vaccine Development and Efficacy Monitoring: NAbs are used to define "correlates of protection." By using genotype-specific NAbs, researchers can evaluate the breadth of the immune response elicited by live-attenuated or subunit vaccines.
• Therapeutic Intervention: Passive immunization with anti-VP4 antibodies has shown promise in reducing the duration and severity of rotavirus-induced diarrhea.
• Viral Entry Mechanism Studies: These antibodies serve as molecular probes to block specific stages of the infection cycle, either inhibiting the initial VP8*-HBGA interaction or preventing the VP5* membrane fusion event.
• Epidemiological Surveillance: Using NAbs in ELISA or neutralization assays allows for the rapid identification and serotyping of circulating strains, which is critical for predicting potential outbreaks.

Our Anti-Rotavirus P Genotypes Neutralizing Antibodies

Creative Biolabs offers an industry-leading selection of Neutra™ antibody products specifically tailored to the study of Rotavirus P genotypes. Our antibodies are validated for high potency in traditional MA104 cell-based assays as well as advanced human intestinal enteroids.

• Monoclonal Anti-VP8* Antibodies: These antibodies target the P[4], P[8], and P[6] genotypes with extreme precision. They are designed for high-affinity blocking of HBGA-binding sites, making them ideal for attachment inhibition studies and diagnostic assay development.
• Broadly Neutralizing Anti-VP5* Antibodies: Focusing on the more conserved regions of the spike protein, our anti-VP5* antibodies provide heterotypic (cross-genotype) protection. By targeting conserved epitopes on the spike stalk, they inhibit the conformational transitions required for viral membrane penetration.
• Polyclonal P-Genotype Panels: For broad surveillance and complex epidemiological studies, we provide comprehensive panels covering P[1] through various zoonotic strains. These are essential for researchers monitoring strain replacement and vaccine escape variants.

Rotavirus P genotypes present a complex challenge in the global fight against pediatric gastroenteritis. Creative Biolabs' Rotavirus P genotypes Specific Neutra™ Antibody Products provide the scientific community with high-precision tools to decode these challenges, from understanding the structural dynamics of the VP4 spike to the development of next-generation vaccines.

For detailed technical specifications, custom antibody development, or to request a quote, please reach out to our specialist team. We are committed to providing the high-end biological reagents necessary to drive your drug discovery forward.

Reference

1. Carossino, Mariano et al. "Equine Rotavirus A under the One Health Lens: Potential Impacts on Public Health." Viruses vol. 16,1 130. 16 Jan. 2024, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/v16010130